Fig. 4From: Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort studyThe improvement of FIB-4 (a) and APRI (b) among patients with receiving SOF-based regimensBack to article page